Multi-Cancer Early Detection Market Projected to Reach 5,153.5 million by 2034 – BIS Research

Market Overview: 

Market Size and Growth Rate 

According to BIS Research, the global MCED market is projected to expand from $1,138.3 million in 2024 to $5,153.5 million by 2034, reflecting a compound annual growth rate (CAGR) of 16.3% over the forecast period.  

Trends & Innovation 

The market is witnessing a surge in the development of liquid biopsy technologies, which analyze circulating tumor DNA (ctDNA) in blood samples to detect cancer. Innovations in next-generation sequencing (NGS) and bioinformatics are enhancing the sensitivity and specificity of these tests. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms is improving the accuracy of early cancer detection, enabling personalized treatment approaches. 

Access insight on multi-cancer early detection (MCED) market 

Key Highlights: 

Report USP: 

• Comprehensive analysis of MCED technologies, including liquid biopsy and gene panel tests. 
• Detailed market segmentation by test type, technology, sample type, end user, and region. 
• In-depth examination of market drivers, challenges, and opportunities. 
• Profiles of key market players and their strategic initiatives. 
• Forecasts and trends shaping the MCED market through 2034. 

Access Sample Report (Including Full TOC, List of Tables, Figures, and Chart)   

Demand Drivers, Challenges & Opportunities: 

Market Drivers: 

The global rise in cancer cases particularly solid tumors like breast, lung, and colorectal cancers is a major factor driving growth in the multi-cancer early detection (MCED) market. As per GLOBOCAN data, cancer diagnoses reached approximately 19.98 million cases in 2022 and are projected to escalate to 24.1 million by 2030. This surge underscores the urgent need for advanced diagnostic tools that facilitate early and accurate detection. Early diagnosis significantly improves survival rates, reduces treatment complexity, and enhances patient quality of life. Detecting cancer in its initial stages often allows for more effective and less invasive treatment. As healthcare systems increasingly prioritize personalized and preventative care, the demand for early detection solutions is expected to rise accordingly. 

Market Challenges: 

Despite their clinical promise, multi-cancer early detection tests face a critical barrier: high cost. These tests typically carry a significantly higher price tag compared to single-cancer screening methods, due to their broader scope and advanced technology. Additionally, limited insurance coverage particularly in markets like the U.S. forces many patients to bear the financial burden out-of-pocket. This restricts access to MCED tests, especially for lower-income populations, and impedes their adoption within publicly funded healthcare systems. As a result, the scalability of these promising diagnostic innovations remains constrained by economic factors. 

Market Opportunities: 

The integration of artificial intelligence into cancer diagnostics is unlocking transformative opportunities in the MCED space. AI-driven tools are enhancing the precision, speed, and affordability of early detection by analyzing complex data from multiple diagnostic sources including blood-based biomarkers, imaging, and genomic profiles. This multi-modal approach allows for more comprehensive and reliable cancer detection, even in asymptomatic individuals. As AI capabilities evolve, their application in early cancer diagnostics is expected to streamline clinical workflows, improve detection rates, and support the development of scalable, population-wide screening programs. 

Market Segmentation: 

Segmentation 1: Technology based segmentation 

•    Next-Generation Sequencing (NGS) 

•    Polymerase Chain Reaction (PCR) 

•    Other Technologies 

Segmentation 2: Sample Type based segmentation 

•    Blood 

•    Saliva and Buccal Swab 

•    Others 

Segmentation 3: End User based segmentation 

•    Hospital 

•    Research Institutes 

•    Others 

Segmentation 4: Region based segmentation 

•    North America 

     o    U.S. 

     o    Canada 

•    Europe 

     o    Germany 

     o    U.K. 

     o    France 

     o    Italy 

     o    Spain 

     o    Rest-of-Europe 

•    Asia-Pacific 

     o    China 

     o    Japan 

     o    India 

     o    Rest-of-Asia-Pacific  

•    Rest-of-the-World  

Competitive Landscape: 

Key Players 

•    GRAIL, Inc. 

•    Guardant Health 

•    Burning Rock Biotech Limited 

•    Natera, Inc. 

•    Exact Sciences Corporation 

Strategic Initiatives 

Companies are focusing on strategic collaborations, mergers and acquisitions, and significant investments in research and development to enhance their product portfolios. For instance, in February 2024, Freenome secured $254 million in funding to advance its multi-omics platform for early cancer detection. Similarly, the National Institutes of Health (NIH) launched a research network to evaluate emerging cancer screening technologies, supporting the Biden-Harris administration's Cancer Moonshot initiative. 

Download the complete TOC now!     

Case Studies & Success Stories: 

GRAIL's Galleri test exemplifies the potential of MCED technologies. Launched as a laboratory-developed test, Galleri can detect over 50 types of cancer through a single blood draw, demonstrating high specificity and sensitivity. Its integration into clinical practice highlights the feasibility and impact of MCED tests in real-world settings. 

Schedule a Call with Industry Experts 

Related Reports from BIS Research 

India Emerging Infectious Disease Diagnostics Market 

Medical X-Ray Detectors Market 

Cell-Free DNA Isolation and Extraction Market 

About BIS Research 

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.   

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.    

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.   

Contact 

Head of Marketing  

Email: media@bisresearch.com    

BIS Research Inc.   

39111 PASEO PADRE PKWY STE 313,   

FREMONT, CA 94538-1686  

Visit our Blog @https://bisresearch.com/insights   

Get Expert Insights @https://community.insightmonk.com    

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research    

Connect with us on Twitter@ https://twitter.com/BISResearch